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Abstract 
Background: Posttraumatic stress disorder (PTSD) is a psychiatric disorder affecting millions of the US 
population. Symptoms and comorbidities of the disorder can dramatically affect the lives the sufferers. 
First-line treatment has been either antidepressants, psychotherapy, or a combination of both. However, 
success rates are lacking. Recently, the beta blocker propranolol has been shown to have effects on 
disrupting memory reconsolidation in humans through inhibitory actions on protein synthesis and 
norepinephrine. This could potentially translate to disrupting the traumatic memories in PTSD and 
becoming an adequate treatment for the condition. 
Methods: An exhaustive literature search of MEDLINE-Ovid, MEDLINE-Pubmed, Google Scholar, and Web 
of Science with the terms PTSD, Posttraumatic stress disorder, reconsolidation, and propranolol was 
conducted. Bibliographies were also searched for relevant studies. The studies were evaluated using 
GRADE criteria. 
Results: A search of currently available research yielded 232 articles, 3 of which met inclusion criteria. 
One of the studies was a meta-analysis from 2013, one study was a continuation from a previous study 
included in the meta-analysis, and one study was a randomized control trial. Decreases in 
psychophysiological response (heart rate and skin conductance) to traumatic imagery with propranolol-
treated subjects was observed and considered statistically significant. A follow-up study also showed 
these results lasted over 4 months. Clinician-administered PTSD scale (CAPS) scores and PTSD Checklist 
(PCL) scores were found to be significantly lower in propranolol-treated PTSD subjects when compared to 
placebo after memory reconsolidation and at follow-up. 
Conclusion: Both early and recent studies have shown promising results of propranolol blocking memory 
reconsolidation in PTSD patients to reduce symptoms, but its routine use in practice would be premature. 
Study limitations and uncertainties warrant the need for extension and replication in larger samples of the 
population. If further studies can duplicate the findings, propranolol use in conjunction with memory 
reactivation exercises may be an effective, safe, and affordable treatment for PTSD. 
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Abstract   
 
Background:  Posttraumatic stress disorder (PTSD) is a psychiatric 
disorder affecting millions of the US population.  Symptoms and 
comorbidities of the disorder can dramatically affect the lives the 
sufferers.  First-line treatment has been either antidepressants, 
psychotherapy, or a combination of both.  However, success rates are 
lacking. Recently, the beta blocker propranolol has been shown to 
have effects on disrupting memory reconsolidation in humans through 
inhibitory actions on protein synthesis and norepinephrine.  This could 
potentially translate to disrupting the traumatic memories in PTSD and 
becoming an adequate treatment for the condition.  
 
Methods:  An exhaustive literature search of MEDLINE-Ovid, 
MEDLINE-Pubmed, Google Scholar, and Web of Science with the terms 
PTSD, Posttraumatic stress disorder, reconsolidation, and propranolol 
was conducted.  Bibliographies were also searched for relevant 
studies.  The studies were evaluated using GRADE criteria. 
 
Results:  A search of currently available research yielded 232 articles, 
3 of which met inclusion criteria.  One of the studies was a meta-
analysis from 2013, one study was a continuation from a previous 
study included in the meta-analysis, and one study was a randomized 
control trial.  Decreases in psychophysiological response (heart rate 
and skin conductance) to traumatic imagery with propranolol-treated 
subjects was observed and considered statistically significant.  A 
follow-up study also showed these results lasted over 4 months.  
Clinician-administered PTSD scale (CAPS) scores and PTSD Checklist 
(PCL) scores were found to be significantly lower in propranolol-
treated PTSD subjects when compared to placebo after memory 
reconsolidation and at follow-up. 
 
Conclusion:  Both early and recent studies have shown promising 
results of propranolol blocking memory reconsolidation in PTSD 
patients to reduce symptoms, but its routine use in practice would be 
premature.  Study limitations and uncertainties warrant the need for 
extension and replication in larger samples of the population.  If 
further studies can duplicate the findings, propranolol use in 
conjunction with memory reactivation exercises may be an effective, 
safe, and affordable treatment for PTSD. 
 
Keywords: PTSD, Posttraumatic Stress Disorder, reconsolidation, 
propranolol  
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Propranolol’s Effects on Memory 
Reconsolidation in Patients with PTSD 
BACKGROUND 
 Posttraumatic stress disorder (PTSD) is a psychiatric disorder 
arising from a traumatic event that has a lifetime prevalence rate of 4-
6% in the United States.1  These events typically include rape, 
childhood abuse, domestic disputes, unexpected deaths/conditions of 
loved ones, experiencing physical injuries from medical issues, 
physical assault, exposure to organized violence, combat exposure, 
motor vehicle accidents, and natural disasters.  People suffering from 
PTSD commonly experience disturbing and intense thoughts related to 
their trauma which can include nightmares, flashbacks, anxiety, fear, 
combativeness, anger, sadness, depression, avoidance, derealization, 
physiological overactivity, and depersonalization.2 These clinical 
manifestations often dramatically affect the individual in many areas of 
their life long after the original trauma.  Comorbid conditions include 
other psychiatric disorders,3 cardiovascular and gastrointestinal 
disease, diabetes, arthritis,4 hypertension,5 and autoimmune 
disorders.6 
 First-line therapy for PTSD has been psychotherapy alone or with 
medications, such as selective serotonin reuptake inhibitors (SSRIs) or 
selective norepinephrine reuptake inhibitors (SNRIs). However, the 
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evidence of success rates are lacking.7,8  SSRIs and SNRIs are the 
most commonly used medications for PTSD but can have significant 
side effects such as sexual dysfunction, insomnia, and increased 
anxiety.  Psychotherapy alone has not been found to adequately treat 
PTSD.8  Combined therapy with SSRIs and psychotherapy has also not 
been found to effectively treat PTSD symptoms.9 Clearly, new 
approaches to treatment need to be considered. 
 Recently, a new approach to treating PTSD involves disrupting 
the reconsolidation of traumatic memories.   The initial consolidation of 
memories involves transferring new memories from short to long-term 
memory.  This is a complex process involving protein synthesis, 
synaptic consolidation within the first few hours of acquiring a new 
memory, and systems consolidation, where hippocampus-dependent 
memories become independent of the hippocampus over a period of 
weeks to years as the memory is continuously recalled.10 The 
consolidation process is thought to make the memory stable in long-
term memory storage.  Conversely, memory reconsolidation involves 
accessing these consolidated memories and reconsolidating them, 
once again, into long-term memory storage.  However, during the 
memory reconsolidation process, the retrieved memory is thought to 
be labile or malleable due to the reconsolidated memory going through 
some of the same processes that occur during consolidation, most 
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notably protein synthesis.11–14  Altering or disrupting this 
reconsolidation process is thought to be a target in modifying or 
updating PTSD memories and symptoms. 
 One of the medications being studied to alter the reconsolidation 
process is the beta blocker propranolol.  Propranolol is a nonselective, 
beta-adrenergic blocker of epinephrine, norepinephrine (NE), and 
voltage-gated sodium channels.15  It’s mechanism of action blocking 
peripheral beta receptors and voltage-gated sodium channels is useful 
for such conditions like hypertension, tremor, tachyarrhythmias, and 
coronary artery disease.  Propranolol is also lipophilic and can cross 
the blood brain barrier exerting inhibitory effects on the central 
nervous system, aiding in the treatment of migraine.16 This central 
inhibitory effect is also one target of memory reconsolidation therapy 
for treatment of PTSD symptoms through effects on protein synthesis 
in the amygdala, which has been found to be hyper responsive in PTSD 
patients.17–19 The other proposed therapeutic use of propranolol is the 
effect of blocking NE as NE is important in the encoding, retrieval and 
reconsolidation of emotional memory.20  Patients with PTSD have been 
found to have elevated levels of NE in their cerebrospinal fluid when 
compared to healthy individuals.21  
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 Studies22 have shown conflicting findings for propranolol to 
prevent the development of PTSD immediately after trauma exposure; 
however, relatively few studies have been performed examining 
propranolol’s inhibitory effects on long-term memory reconsolidation.  
Can propranolol effectively diminish memory reconsolidation in PTSD 
patients? 
METHODS 
 An exhaustive literature search of MEDLINE-Ovid, MEDLINE-
Pubmed, Google Scholar, and Web of Science was conducted using the 
keywords: PTSD, posttraumatic stress disorder, reconsolidation, and 
propranolol.  Bibliographies were also searched for relevant studies.  
Further refinement of search strategies included studies relevant to the 
topic, data extracted from human studies, and studies done in the 
English language.  Relevant articles were assessed for quality using 
the Grading of Recommendations, Assessment, Development and 
Evaluation (GRADE).23  
RESULTS 
 The initial search yielded 232 results, some of which were 
duplicates.  One of the returned results was a meta-analysis22 from 
2013 evaluating propranolol’s effects on long-term emotional memory.  
Memory reconsolidation blockade in PTSD was included as a subsection 
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of the meta-analysis and only the results from the 2 studies24,25 
evaluating those specific parameters were included in this systematic 
review.  Following elimination of duplicate studies and screening of 
relevant articles performed in human populations and in the English 
language, a total of another 2 relevant studies, done since 2013, met 
eligibility criteria and were included.  One of the included articles26 was 
a continuation of a previous study included in the meta-analysis which 
was an open-label study.  The other relevant study was a randomized 
control trial (RCT).27 See Table 1. 
Lonergan et al 
 Lonergan et al22 conducted a meta-analysis in 2013 to assess 
propranolol’s effects on consolidation and reconsolidation of long-term 
emotional memory. For the sake of this review, only the studies 
regarding memory reconsolidation in PTSD patients will be discussed.  
Both of these studies were performed by Brunet et al.24,25  
Study 1 - The purpose of this study by Brunet et al25 was to 
examine the effects of trauma post-reactivation propranolol use on 
physiologic responses as compared to placebo.   
Nineteen participants with chronic PTSD, according to DSM-IV, 
described the traumatic event that caused their PTSD as a means of 
reactivating their traumatic memory in writing.  Immediately following 
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reactivation, participants were either given 40 mg of short-acting (SA) 
propranolol followed 2 hours by 60 mg long-acting (LA) propranolol or 
similar appearing placebo capsules.  Later, a researcher composed and 
recorded 30 second scripts portraying the traumatic event.  One week 
later, subjects returned and listened to the recorded scripts while 
imagining the event.  Measured physiologic responses were measured 
at baseline and during the reactivation script and included heart rate 
(HR), skin conductance (SC) and left corrugator electromyogram 
(EMG).  The optimal PTSD cut-offs for these measurements were 
previously determined using data from 152 individuals with (n = 79) 
or without (n = 72) PTSD who had gone through the same 
procedure.26 Responses were calculated by subtracting the mean 
baseline physiological measurements from the mean imagery period 
measurements. The participants were randomized by the study’s 
physician with 9 of the participants receiving propranolol and 10 
participants receiving placebo.  The physician kept the other 
investigators and the subjects blind as to his allocation.  He did not 
participate in the experimental protocol outside of administering 
medication and medical monitoring.  
Results showed physiologic responding to the traumatic event 
was significantly smaller in the participants who received propranolol 
(p=0.007).  HR and SC were determined to be the most significantly 
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lowered values in the propranolol group compared to the placebo 
group by univariate analyses. 
Study 2 - This study, conducted by Brunet et al (2011),24 
consisted of 3 open-label trials which explored if more significant 
improvements could be seen in participants administered propranolol 
with trauma reactivation exercises over a greater number of treatment 
sessions and if the improvement was longer lasting. 
Inclusion criteria included participants aged 18 to 65 years of 
age meeting DSM-IV criteria for chronic PTSD.  Exclusion criteria 
included: history of traumatic brain injury; a current or past psychotic, 
bipolar, or substance dependence disorder; a previous adverse 
reaction to a beta blocker; current use of medications that could 
adversely interact with propranolol; conditions such as asthma, heart 
problems, or diabetes that would contraindicate the use of propranolol; 
pregnancy or breast feeding; or participation if any form of 
psychotherapy.24 
 Trial 1. This study involved 28 participants recruited via 
the newspaper in Montreal, Canada who would be evaluated at 
pretreatment, 6 weekly treatment sessions. The participants all had 
experienced a traumatic event meeting criterion A for PTSD diagnosis 
and included motor vehicle accidents, participation in a military UN 
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peacekeeping mission, physical assault, assault with a weapon, sexual 
abuse, incest, physical abuse in childhood, or others.  Comorbid 
conditions in participants included major depressive disorder (n=8), 
social phobia (n=8), obsessive-compulsive disorder (n=6), generalized 
anxiety (n=5), panic disorder with or without agoraphobia (n=7), 
anorexia nervosa (n=1), and bulimia (n=3).  Participants were 
reimbursed up to $250 on a pro-rated basis.24 
PTSD symptom measurement and diagnosis was determined by 
the Clinician-Administered PTSD scale (CAPS) before and after 
treatment and at follow-up.  Timing of the follow-up was unspecified.  
Additionally, the PTSD checklist (PCL) was given weekly during the 6 
treatments to determine intersession improvement.  PTSD was 
diagnosed with the Structured Clinical Interview for DSM-IV.24   
 A dose of 0.67 mg/kg of SA oral propranolol was administered 
during the first session.  Ninety minutes later, an additional 1 mg/kg of 
LA oral propranolol was given.  LA propranolol was not given if systolic 
blood pressure (BP) decreased by 10 mm Hg or more to lower than 
100 mm Hg and if the SA dose was not tolerated well.  The average 
doses given were 47.8 mg SA and 71.1 mg LA.  Immediately after 
given the LA dose, participants provided a written account of the 
traumatic event that led to their PTSD.  During subsequent sessions, 
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SA and LA propranolol doses were given simultaneously. Ninety 
minutes later, subjects were instructed to read aloud the written 
account of their traumatic event.24  
Results showed mean CAP score improvements at pretreatment, 
posttreatment, and follow-up (71.8, 45.8, and 42.7; p<0.001, 
respectively).  Twenty of the 28 participants no longer met full criteria 
for PTSD at follow-up.  PCL scores also significantly decreased across 
time (p<0.001).24  
Trial 2. This trial involved 7 participants recruited by word of 
mouth in Boston, Massachusetts.  Provoking traumatic events included 
motor vehicle accident, physical assault, assault with a weapon, rape, 
witness to family member’s illness, and military combat.  Comorbidity 
included major depressive disorder (n=3) and panic disorder without 
agoraphobia (n=2).  Assessment using CAPS was identical to trial 1 
with a specified follow-up at six months.  PCL scores were not used.  
Propranolol administration protocol was the same as trial 1; however, 
this study used fixed doses of 40 mg SA and 80 mg LA.  Participants 
also provided an oral account of the initiating traumatic event rather 
than a written account during the first session.  In subsequent 
sessions, the account was orally repeated to initiate reactivation.24 
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 Five of the 7 participants no longer met PTSD diagnostic criteria 
at follow-up.  Mean CAPS scores significantly decreased (pretreatment 
68.4, posttreatment 35.6, and follow-up 34.1).24 
 Trial 3. The trial, set in Toulouse, France, was part of an ongoing 
longitudinal study examining the long-term effects of an industrial 
disaster and involved 32 participants.  This trial was unique in that it 
had a control group of 25 subjects who refused treatment but agreed 
to be a part of the study.  Seven participants were treated with 
propranolol.  Outcome measures were PCL scores measured at 6 
months post-disaster, before treatment, after treatment, and follow-up 
at six months.  Treated subjects took part in 6 treatment sessions, 
similar to trial 1 and 2.  Comorbidity in treated participants included 
major depressive disorder, generalized anxiety disorder, and 
agoraphobia without panic.  Propranolol administration at first visit 
was the same as trial 2.  Subsequent sessions only administered 80 
mg of LA propranolol.  Treatment protocol of reactivation was identical 
to trial 1.24 
 Mean PCL scores in the treatment group at 6 months post-
disaster, pretreatment, posttreatment, and follow-up were 60.9, 60.7, 
41.0, and 38.4, respectively.  Control group values were 59.7, 61.7, 
58.7, and 58.7.  Groups did significantly differ at posttreatment and 
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follow-up (p < 0.01).  Six of the 7 treated participants no longer met 
the criteria for PTSD at follow-up, compared with 2 (8%) of the 25 
untreated participants (P < 0.001).  
Brunet et al (2014) 
 Brunet et al27 conducted a continuation study in 2014 from a 
previous open-label trial done in 2011.24 In a previous study, 
discussed in the meta-analysis, Brunet et al25 demonstrated that 
participants with PTSD showed lower physiologic response during 
script-driven traumatic imagery 1 week after receiving a single dose of 
propranolol given after the retrieval of a traumatic memory.  This 
study lacked an adequate follow-up to determine if the effects were 
long-lasting. The purpose of this 2014 study was to determine if these 
physiological effects were also seen in participants from the previous 
open-label trial done in 2011, which was a longer duration study.24 
The 2011 study results are discussed above.  
 An independent research assistant conducted a script-driven 
imagery procedure between treatment and posttreatment in 22 
participants from the 2011 study.  Two of the original participants 
were lost to follow-up and 4 had unusable SC data.  This was done 1 
week after the treatment of 6 weekly visits where participants read an 
account of their traumatic event following oral administration of 0.67 
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mg/kg of SA propranolol and 1 mg/kg of LA propranolol.  The patients 
SC, HR, and left corrugator EMG were recorded during a 30-second 
baseline period and a period after listening to 4 audio-recorded scripts 
(2 portraying the participant’s traumatic event and 2 portraying 
neutral events), where participants “imagined the event as if it were 
happening” for 30 seconds. The change in physiological scores was 
calculated by subtracting the baseline mean value from the mean 
value of the imagery period that followed the scripts.  There was also a 
26-week follow-up where the same procedure was replicated.27 
 A composite measure of psychophysiological reactivity during 
imagery was obtained on each participant. This provided a single score 
(posterior probability) displaying a person’s overall psychophysiological 
reactivity during imagery and the likelihood that their score belonged 
to a calibration sample’s PTSD group.  The calibration sample 
consisted of HR, SC, and EMG responses from previously studied 
participants27 who had been exposed to trauma and either had or did 
not have PTSD.  The previous participants with a posterior probability 
greater than 0.5 were considered to have a greater than 50% chance 
of having a current diagnosis of PTSD and were put into the PTSD 
group.  If the participants had a posterior probability less than 0.5, 
they were assigned to the non-PTSD group.27 
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 The posttreatment HR, SC, and EMG responses from the 22 
participants were then compared with responses from the initial 
psychophysiological study25 where 9 patients received placebo and 10 
patients received propranolol.27  
 According to the discriminant function analysis, 20 (91%) of the 
22 participants were classified as non-PTSD at posttreatment.  
Twenty-one (96%) of the participants were classified as non-PTSD at 
follow-up.27 
 MANOVA and ANOVA analyses comparing the 22 current 
propranolol participants, the 10 previous propranolol patients, and the 
previous 9 placebo patients found a significant main effect for 
physiological responding (p < 0.05) and significant group differences 
for SC (p <0.001) and HR (p < 0.05), but not EMG (p = 0.48). The 
mean score of the current propranolol group’s SC and HR was 
significantly smaller than the previous placebo group.  There were no 
significant differences between the present and previous propranolol 
groups for SC or HR.27 
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Brunet et al (2018) 
 This recent RCT28 from 2018 was aimed at evaluating the 
efficacy of using propranolol during trauma memory reactivation 
exercises to reduce symptoms of PTSD.  
 Participants were recruited via referrals and local advertisement.  
Inclusion criteria included: patients aged 18-65 years of age with PTSD 
who were seeking treatment, patients who had PTSD for at least 6 
consecutive months, patients who scored ≥ 44 on the PCL-S at intake, 
patients who were fluent in French or English, and patients who lived 
in Montreal.  Exclusion criteria included: basal HR <55 beats per 
minute, medical conditions (asthma, diabetes, arrythmia, or 
congestive heart failure) that would contraindicate the use of 
propranolol, lifetime psychotic or bipolar disorder, traumatic brain 
injury, current substance dependence, acute suicidal ideation, current 
use of medication that could interact adversely with propranolol (anti-
arrhythmic or calcium channel blocker), pregnant or breast feeding, 
receipt of psychotherapy for PTSD during treatment phase, 
involvement in PTSD-related litigation, or strong dissociative 
tendencies (average score of >20 on the Dissociative Experiences 
Scale).  Patients taking antidepressants were included in the study but 
were asked to delay their medication by a few hours on treatment 
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days.  A total of 61 participants met inclusion criteria and were 
randomly assigned to six treatment sessions.  One participant from the 
placebo group was excluded due to invalid data, leaving 30 
participants to be analyzed in the active treatment group and 30 
participants in the placebo group.  Participants who adhered to the 
study at the seventh- and twenty-sixth-week assessments were given 
$50.  Follow-up was conducted at 6 months.28 
 The CAPS and PCL-S were used to assess effectiveness of 
treatment.  The Mini International Neuropsychiatric Interview version 
5.0 was used to assess pretreatment comorbidity of 17 other DSM IV 
axis I mental disorders.  CAPS was administered 1 week before, 1 
week after, and 6 months follow-up treatment to provide a PTSD 
symptom score and a formal DSM IV diagnosis of PTSD. The PCL-S 
was administered at the beginning of each treatment session, before 
propranolol administration, to assess the previous week’s symptoms.  
The CAPS and PCL-S scores were compared between baseline and 
posttreatment.  CAPS follow-up data were only available for 14 
participants.28 
 As in previous studies,24 0.67 mg/kg of SA oral propranolol, plus 
1.0 mg/kg of LA propranolol was given.  However, during the first 
session, instead of 90 minutes elapsing between doses, they used a 2-
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hour delay to assess for adequate medication tolerance.  Also, during 
subsequent sessions they administered both medications 
concurrently.28 
 They used the Douglas Institute pharmacy at McGill University to 
maintain randomization schedule and to prepare and dispense the 
medication.  All medication packages were the same and empty 
packets were kept in the participant’s file to assess for adherence.28 
 Vital signs and symptoms were monitored before administration 
and every 30 minutes for 90 minutes until trauma reactivation 
exercises began.  Six of the 60 participants reported side effects and 
were excluded from further participation.28 
 Trauma reactivation was performed by a doctorate-level 
therapist who was blinded to group status and trained by the lead 
author, Alain Brunet. At 1 hour after medication administration, the 
participants were instructed to write a single page narrative about the 
trauma they experienced focusing on the event’s most disturbing 
moments and including 5 or more bodily sensations drawn from a 
checklist.  The participant was then asked to read the written narrative 
aloud “as if they were back in the event.”  During each subsequent 
visit, the participants were asked if they needed to add or remove any 
details to the narrative before once again reading it aloud.28 
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 The researchers performed an intention-to-treat analysis (ITT) 
on the initial 60 participants and a per protocol analysis (PP) on the 30 
participants (15 treatment, 15 placebo) who completed at least 5 
treatment sessions.  Analysis of covariance was used to test for a 
between-group difference in post-treatment CAPS score and adjusted 
for pretreatment score.28 
 Results displayed decreased CAPS scores in both groups for ITT 
analysis (propranolol mean baseline and posttreatment, 76.07 and 
47.16; placebo mean baseline and posttreatment, 71.04 and 53.69), 
but decreases were significantly higher in the propranolol group. The 
estimated posttreatment between-group difference, which was 
adjusted for baseline score, was 11.50 (p=0.034).  The ITT and PP 
pre- to posttreatment CAPS improvements were 38% and 36% in the 
propranolol group and 24% and 13% in the placebo group, 
respectively.  Results were similar for PP scores with an estimated 
posttreatment between-group difference of 16.30 (p=0.037).28 
 PCL-S scores also decreased in both groups for ITT with higher 
decreases in the propranolol group (propranolol mean baseline and 
posttreatment, 61.18 and 36.60; placebo mean baseline and 
posttreatment, 61.27 and 55.71).  The intention-to-treat and per 
protocol pre- to posttreatment PCL-S improvements, respectively, 
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were 56% and 53% in the propranolol group and 15% and 10% in the 
placebo group.  PCL-S scores decreased an average of 2.43 points per 
week in the ITT analysis and 2.79 points in the PP analysis in the 
propranolol group.28 
DISCUSSION 
 All the studies24-28 included in this review found that propranolol 
had beneficial effects on PTSD symptoms in patients who took the 
medication either before or after the memory reconsolidation 
technique.  The administration of propranolol along with memory 
reactivation decreased mean CAPS scores up to 38% in the RCT 
conducted by Brunet et al (2018)28 with up to 70% of subjects no 
longer meeting PTSD diagnostic criteria in the open-label trials.24 PCL 
scores decreased anywhere from 45% to 56% from pretreatment to 
posttreatment.24,28 Psychophysiological responses such as HR and SC 
to trauma reactivation decreased to levels of trauma patients without 
PTSD when compared to placebo,25 and the results were enduring.27  
Other case studies have shown similar effects in treating PTSD 
symptoms during memory reconsolidation with propranolol after only 
one to two treatment sessions.29 
The study from 2007,25 specifically examining the effects on 
physiological responses, administered the propranolol immediately 
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following the first reactivation exercise.  In contrast, all of the 
remaining studies administered the medication prior to the trauma 
memory reactivation. Potentially, administering propranolol before 
reactivation could lead to effects on retrieval of the material.  In the 
meta-analysis, this issue is discussed.22  Studies have found that 
propranolol has no effect on brain mechanisms activated during 
reactivation,22 ruling out any effects on retrieval of the memory, 
although this could be potentially studied more in detail.  
 Although Brunet et al25 used propranolol following memory 
retrieval in the 2007 study, he explains that due to reconsolidation 
starting 3-10 minutes after memory reactivation, most reconsolidation 
done in the first 2 hours, and with propranolol reaching peak 
bioavailability in 90 minutes, the administration of propranolol 
following memory retrieval may be too late to be effective.30  This was 
also examined in a later study.31 As a result of this, Brunet and his 
colleagues opted to use propranolol before reactivation in later 
studies,24,28 despite showing decreased physiological responses with 
post-reactivation propranolol administration in his 2008 study.  
Interestingly, in a comparative study where researchers provided 
propranolol prior to reactivation in combat-related PTSD subjects,33 
results failed to replicate the findings of Brunet et al’s. 
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In all the studies,24-28 reconsolidation of memories through 
reactivation was the target for propranolol’s usage.  However, it is 
difficult to determine if propranolol was actually blocking 
reconsolidation or enhancing extinction.33  In Brunet et al’s 
studies,24,27,28 participants either described or listened to their 
traumatic event continually over multiple treatments.  This, in effect, 
could be considered extinction training since they were continually 
exposed to their traumatic event.  Brunet et al (2007)24 did attempt to 
minimize the effects of extinction by maintaining a shorter treatment 
session, but it is difficult to distinguish whether the effect was due to 
reconsolidation, extinction, or a combination of both.  Brunet goes on 
to further explain that reconsolidation differs from extinction in that 
extinction training typically has longer treatment periods and that 
extinction training tends to inhibit traumatic memories, while 
reconsolidation blockade has a tendency to weaken or erase the 
original memory in a shorter amount of time.24,28 
Other methods of interfering with reconsolidation have been 
considered.  The Reconsolidation of Traumatic Memories Protocol 
(RTM) has recently shown promising results.34-35 The process of 
memory reactivation and reconsolidation are essentially the same, 
however, participants are taken through a series of visual imagery 
exercises to dissociatively modify or restructure the traumatic 
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memory.  The protocol is completed over the course of three to five 
90-minute long sessions administered over a five to ten-day period.  
In one study, 26 male veterans completed the RTM protocol with a 
mean-treatment reduction of 33 points on the PCL military version 
(PCL-M) after 6 weeks.34 Studies could potentially be conducted using 
both propranolol and RTM, or comparing the two, to further expand 
the research being conducted on memory reconsolidation blockade. 
Obviously, there were limitations to the studies included, along 
with possible bias.  Larger sample sizes would be of benefit along with 
adequate follow-up.  Follow-up values were obtained in some 
studies24,27,28 although some had lost an adequate number of 
participants, which could lend to a risk for attrition bias.27  The extent 
of blinding and allocation was discussed in some studies, but did not 
adequately address the degree to which blinding occurred for 
participants and researchers, alike.  Additionally, Alain Brunet, Ph.D. 
was included in each study which could potentially lead to publication 
bias. 
 
CONCLUSION 
 Studies have shown promising results of propranolol blocking 
memory reconsolidation in PTSD patients to reduce symptoms, but its 
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routine use in practice would be premature.  Study limitations and 
uncertainties warrant the need for extension and replication in larger 
samples of the population.  If further studies can duplicate the 
findings, propranolol use in conjunction with memory reactivation 
exercises may be an effective, safe, and affordable treatment for 
PTSD.  
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Table 1: Quality Assessment of Reviewed Articles 
Outcome 
Number 
of studies 
Study 
Designs 
Downgrade Criteria 
Upgrade 
Criteria 
Quality 
Limitations Indirectness Inconsistency Imprecision 
Publication 
bias 
Reduction of 
Physiological 
Responses24,27 
2 Open-label, 
Case control 
studies 
Seriousa Not 
Seriousb,c 
Not Serious Seriousd Likelye  Very 
Low 
Reduction of CAPS 
and CPL-S 
Scores24,28 
2 Open-label, 
RCT 
Not 
Serious 
Not seriousb Not Serious Seriousd,f Likelye  Low 
a Lack of blinding of data collectors and patients in both 
b Unclear whether propranolol works directly on memory reconsolidation, although it is hypothesized 
c Did not include results of physiological testing in original open-label study.  Results of this were disclosed in future study. 
d Small sample size 
e Alain Brunet is an author included in every study 
f Risk of attrition bias 
 
